Unique ID issued by UMIN | UMIN000014971 |
---|---|
Receipt number | R000017401 |
Scientific Title | Comparison of DAAs(Direct Acting Antivirals) and interferon-based triple therapy for hepatitis C after treatment of hepatocelluler carcinoma. |
Date of disclosure of the study information | 2014/09/01 |
Last modified on | 2018/08/30 15:15:09 |
Comparison of DAAs(Direct Acting Antivirals) and interferon-based triple therapy for hepatitis C after treatment of hepatocelluler carcinoma.
Antiviral therapy for HCV after treatment of hepatocelluler carcinoma.
Comparison of DAAs(Direct Acting Antivirals) and interferon-based triple therapy for hepatitis C after treatment of hepatocelluler carcinoma.
Antiviral therapy for HCV after treatment of hepatocelluler carcinoma.
Japan |
Hepatitis C after treatment for hepatocelluler carcinoma.
Hepato-biliary-pancreatic medicine |
Others
YES
To clarify the antiviral therapy for inhibition of recurrence after treatment for hepatocelluler carcinoma.
Efficacy
incidence of recurrence
survival rate
Observational
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1) HCV genotype 1b
2) Neutrophil >=1,500 /mm3
PLT >= 75,000 /mm3
3) >=3 months post HCC treatment
4) CH or LC(Child-Pugh A)
5) within HCC stage 3
6) including post PSE/splenectomy cases
Patients judged by doctor that participation in the study is improper
100
1st name | |
Middle name | |
Last name | Kouji Joko |
Matsuyama Red Cross Hospital
Center for liver-Biliary-Pancreatic Diseases
1 Bunkyo-cho, Matsuyama-shi, EHIME
089-924-1111
Koujijoko@matsuyama.jrc.or.jp
1st name | |
Middle name | |
Last name | Toshie Mashiba |
Matsuyama Red Cross Hospital
Center for liver-Biliary-Pancreatic Diseases
1 Bunkyo-cho, Matsuyama-shi, EHIME
089-924-1111
matoshi@matsuyama.jrc.or.jp
Musashino Red Cross Hospital
Japan Agency for Medical Research and Development
Other
NO
2014 | Year | 09 | Month | 01 | Day |
Partially published
Main results already published
2014 | Year | 08 | Month | 25 | Day |
2014 | Year | 09 | Month | 01 | Day |
Comparison of DAAs(daclatasvir and asunaprevir) and interferon-based triple therapy for hepatitis C after treatment for hepatocelluler carcinoma in Red Cross Hospital in Japan.
2014 | Year | 08 | Month | 27 | Day |
2018 | Year | 08 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017401
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |